Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
JCO Oncology Practice|February 8, 2023
Impact of a Biopsychosocial Screening Program on Clinical and Hospital-Based Outcomes in CancerCristiane Decat Bergerot, Paulo Gustavo Bergerot, Lorena Nascimento Manrique Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
JCO Global Oncology|March 26, 2026
Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey StudyPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Errol J Philip, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEAGuilherme Piovezani Ramos, Daniel Zeve, Amy Shepherd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
Journal of Geriatric Oncology|May 2, 2025
Enhancing quality of life in older adults with cancer: Outcomes of a 12-week supervised remote exercise interventionPaulo Gustavo Bergerot, Cristiane Decat Bergerot, Jonas Ribeiro Gomes Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
JCO Oncology Advances|April 29, 2026
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyEllen M Lavoie Smith, Minji Lee, Mary R Scott, et al.
JCO Oncology Practice|April 7, 2025
Assessment of Compliance With ASCO Language of Respect Guidelines in Renal Cell Carcinoma AbstractsNazli Dizman, Ruchi Agarwal, Daniela V Castro, et al.
Pageof 7